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ABSTRACT 
     Although the conventional therapies have obviously improved the conditions of patients with cancer, 
some mechanisms of resistance have led scientists to use alternative agents that can penetrate in most solid 
tumors. Furthermore, the success of cancer therapies depends on limiting the uptake of toxins to normal 
tissues and their selectivity towards malignant cells. The involvement of natural and genetically modified 
non-pathogenic bacterial species, as potential antitumor agents, has led scientists to study bacteria and their 
products as an ideal vector for delivering therapeutic components to tumors. Moreover, bacterial ghosts, 
microbots and bactofection are the other strategies to destruct the malignant tissues. Although it has shown 
to achieve successful results in vivo, further investigations on the targeting mechanisms of the bacteria are 
needed to make it a complete therapeutic approach in cancer treatment. 
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INTRODUCTION  
     Cancer occurs when tumor cells grow, invade, 
and spread into the surrounding normal tissues 
uncontrollably; this process is called metastasis. 
Although treatment of cancer can involve several 
modalities such as resection, radiotherapy, and 
chemotherapy, other strategies have developed 
with the aim of improving cancer therapies. 
Experimental cancer treatments are medical 
therapies, including photodynamic therapy, 
Human Alphalactalbumin Made Lethal to Tumor 
Cells, gene therapy, telomerase therapy, 
hyperthermia therapy, dichloroacetate (DCA), 
non-invasive RF cancer treatment, 
complementary and alternative therapy, diet 
therapy, insulin potentiating therapy, and bacterial 
treatment, which have been considered as 
alternative treatments to replace conventional 
methods; yet, due to lack of evidence, efficacy, 
feasibility, availability, specificity, and 
selectivity, the prevalent use of these therapies in 
cancer therapy has become controversial [1]. 
Some microorganisms have been shown to 
selectively replicate in tumor cells such as many 
viruses, like vaccinia virus, Newcastle disease 
virus, reovirus, and adenovirus with an E1a 
deletion, which carry altered genes to cancer cells, 
find target cells in body, and destroy them. and 
yet, sometimes body procures neutralizing 
antibody against these microorganisms which 
leads to deactivation of their efficacy [2]. Some 
bacterial species are able to enter and then 
replicate within tumor cells, simultaneously carry 
and express multiple therapeutic proteins, and 
consequently be eliminated by antibiotics [3]. 
Furthermore, in many infectious diseases and 
cancer, to deliver genes, live attenuated strains of 
bacteria should be applied, which have different 
advantages, including low-cost preparation, 
intensive immune stimulation, tolerance, safety, 
and the major point of antigen entry into the 
Major Histocompability Complex class I pathway 
for the induction of cytotoxic T cells [4]. 
Therefore, the advent of advanced techniques, 
including bacterial drug delivery as bacterial 
vectors for genetic manipulation has created novel 
bioengineered microbes with great therapeutic 
efficacy in many therapeutic strategies including 
apoptosis induction, suicide gene therapy, 
immunotherapy, anti-angiogenesis therapy, and 
DNA vaccination [5]. The present review 
 




highlights bacteria as a vehicle of new delivery 
system with no cytotoxicity and high efficiency, 
which can make it an alternative pathway to treat 
cancer cells. 
Bacteria to Treat Infectious Diseases 
The role of bacteria as anticancer agent has been 
recognized about a hundred years ago. The first 
observations of bacteria treating infectious 
diseases was reported in 1813 when Vautier 
understood that cancer patients who were 
suffering from a gas gangrene infection (often 
caused by bacteria called Clostridium 
perfringens), underwent tumor regression [6]. In 
the late 1800's, an American physician, William 
Coley, while examining his patient suffering from 
neck cancer could recover infection, for the first 
time, with live cultures of S. pyogenes and a few 
days later with killed extracts of S. pyogenes and 
Serratia marcescens, which were called Coley's 
toxins [7, 8]. Therefore, bioengineered bacteria 
based on Coley's toxins have been the basis for 
current advanced studies. 
Bacteria in Cancer Therapy 
The lack of selectivity towards tumor cells, 
despite making progress in tumor-targeting 
technologies, has led to limitations in the current 
cancer therapies. Some species of anaerobic 
bacteria, such as genus Clostridium (like 
Clostridium beijerinckii, Clostridium novyi-Non 
Toxigene, C. histolyticum), have a natural ability 
to target tumors, prosper, and consume oxygen-
poor cancerous tissues; hence, they can colonize 
only within the necrotic and hypoxic areas of 
tumors, and as a result, microbial growth within 
the tumor can result in a strong cytolytic and 
oncolytic effects. Clostridia can express IL-2 and 
TNFa with the property of stimulating antitumor 
immunity and direct antitumor features by genetic 
modifications [9]. Moreover, these families can 
produce spores that reach an oxygen deprived 
area of a tumor where they germinate, multiply, 
and become active [10]. According to the strategy 
of ―combination bacteriolytic therapy‖ 
(COBALT), C. novyi-NT spores are used in 
combination with several chemotherapeutic 
agents, such as docetaxel, vinorelbine, mitomycin 
C., and dolastatin-10 [11]. Making use of genetic 
engineering to increase the antitumor clostridial 
spore’s activity, some prodrug converting 
enzymes such as cytosine deaminase with the 
ability to converting 5-fluorocytosine (5-FC) to 5-
fluorouracil (5- FU) along with high local 
concentrations of cytotoxic drug can be used so as 
to cause less damage to healthy tissues [12]. 
Despite the lack of clinical toxicity, as delivery 
agents, bacterial spores are commonly ineffective 
against small metastases [13, 14]. Gram-positive 
anaerobes, such as Bifidobacteria, can reinforce 
induction of tumor-specific T cells and increase 
selective accumulation of antigen-specific CD8+ 
T cells in the tumor and thus destroy them 
[15].The antitumor properties of facultative 
anaerobes, including L. lactis and Salmonella 
enterica subsp. enterica serovar Typhimurium, 
have profoundly been studied. To treat 
inflammatory bowel disease and moderate 
ulcerative colitis, natural non-pathogenic L.lactis 
as a therapeutic agent, which is administered 
orally, can produce IL-10 [16]. An attenuated 
Salmonella typhimurium strain has chromosomal 
deletion in two regions of its genes like msbB 
(reduction endotoxicity results in inducing 
mutation in the components of the 
lipopolysaccharide by preventing the addition of a 
terminal myristyl group to the lipid A domain) 
and purI (deletion creates a requirement for an 
external source of adenine). The mutation lowered 
the toxicity in mice by reducing the induction of 
pro-inflammatory cytokines and nitric oxide 
synthase. Thus, the organism is able to replicate 
in normal tissue such as the liver or spleen, but it 
is still capable of growing in tumors where 
available purines become essential to survival [17, 
18]. Another property of Salmonella, in addition 
to invasion and induction of apoptosis in tumor 
cells, is the ability to penetrate within a tumor 
mass due to its motility and moving away from 
the vasculature of metastases [19]. Leucine and 
arginine released from tumors have been 
indicated to have high level of sensitivity and 
specificity between auxotrophic Salmonella 
strains in xenograft models of metastatic cancer in 
mice [20]. Systemic injection of engineered 
attenuated S. Typhimurium with TNF-Related 
Apoptosis-Inducing Ligand under the control of 
recA and also using γ irradiation are shown to 
 




inhibit mammary carcinoma cell proliferation 
[21]. Furthermore, under the control of a 
Cytomegalovirus promoter, Fas ligand, hIL-12, h 
GM-CSF, mIL-12, m GM-CSF, IL-2 (which 
increases Natural killer cells) and 
immunomodulatory molecules like IL-18, 
chemokine CCL21 and LIGHT, a cytokine known 
to promote tumor rejection, have been cloned in 
an attenuated S. Typhimurium. As a result, 
angiogenesis is decreased and apoptosis or 
necrosis within the tumor tissue is increased [22-
25]. The main advantage of using salmonella is its 
ability to grow rapidly under aerobic and 
anaerobic conditions. In anaerobic condition, S. 
Typhimurium carrying the gene for cytolysin 
(HlyE) under the control of a cell-specific 
promoter (hypoxia-inducible promoter), after 
systemic injection, could quickly migrate into 
hypoxia areas and diminish tumor growth [26]. In 
bactofection strategy, bacteria containing the 
naked plasmid DNA under the control of 
eukaryotic promoters can enter mammalian cells. 
Then, bacterial vectors may escape from 
phagosome to the cytosol of infected host cells to 
replicate and deliver the DNA directly into these 
cells [27, 28]. The recent studies have illustrated 
that some other bacteria like Shigella flexneri [27, 
29, 30], Salmonella spp [27, 31], E. coli [27, 29, 
30, 32], and Yersinia enterocolitica [33] can be 
used as transport molecules. Since the 
Salmonella, Yersinia, and E. coli stay inside the 
vacuolar phagosome of infected host cells, 
entering into the host cells’ nuclei, where 
transcription of plasmid DNA occurs, is 
fundamentally unknown, yet according to 
different studies, releasing of the plasmid DNA 
happens either spontaneously or by antibiotics or 
application of auxotrophic mutants [29, 30]. A 
good example of using bacterial vectors is 
Lovaxin-C. This component is a recombinant 
live-attenuated Listeria monocytogenes which 
secretes the antigen HPV-16 E7 fused to a non-
hemolytic listeriolysin O protein. In phase I of the 
study by Radulovic, promising specific T-cell and 
clinical response, with no serious adverse was 
detected in cervical cancer patients [34].  
Bacterial toxins as the promising strategy to 
treat cancer  
Bacterial toxins can be used for demolition of 
tumor cells or, at low concentrations; they alter 
cellular processes that control cell cycles, such as 
cell proliferation, apoptosis, and differentiation.  
These alterations could be shown in two 
conditions: firstly cell-cycle inhibitors, such as 
Cytolethal Distending Toxins, that cause cell 
block before entering into mitosis and the Cycle 
Inhibiting Factor (CIF) are injected to eukaryotic 
cell via a type III secretion system using 
pathogenic intracellular bacteria like 
Burkholderia pseudomallei cif (also known as 
CHBP) that converts glutamine 40 of NEDD8, 
which exerts important conformational control 
required for Cullin RING E3 ubiquitin Ligases 
(CRL) activity to glutamate (Q40E), which causes 
cytopathic effects and inhibits cell proliferation 
and secondly cell-cycle stimulators, such as the 
Cytotoxic Necrotizing Factor triggers G1–S 
transition to induce DNA replication. Then, not 
only has the number of cells do not increase, but 
the cells become multinucleated due to the toxin's 
ability to inhibit cell differentiation and apoptosis 
[35-37]. Certain bacterial toxins act through 
binding to antigens present on tumor surface, like 
Diphtheria toxin and Peudomonas exotoxin A, 
known to catalytically ribosylate EF-2 and lead to 
inhibition of protein synthesis accompanied by 
lysis cell and induction of apoptosis [38-40]. 
Clostridium perfringens enterotoxin (CPE) on 
type A strain is able to inhibit tumor growth in 
vivo. The C-terminal domain of toxin is 
responsible for high affinity binding to the CPE 
receptor and the N-terminal is supposed to be 
essential for cytotoxicity [41, 42]. Previous 
studies have indicated that the cytotoxic effects of 
CPE are thought to be useful as a novel 
therapeutic pathway on pancreatic cancer cells 
that led to tumor necrosis and inhibition of tumor 
growth [43]. Botulinum Neurotoxin is shown to 
have antitumor effect on the tumor 
microenvironment rather than affecting directly 
on tumor cells and can also grow in tumor blood 
vessels, making a window of opportunity for 
destruction of cancer cells by radiotherapy and 
chemotherapy [44]. Based on studies on some 
different bacterial toxins like alfa-toxin from 
Stapylococcus aureus, adenylate cyclase toxin 
 




from Bordetella pertussis, shiga-like toxins, and 
cholera toxin on two cell lines, such as 
mesothelioma cells (P31) and small lung cancer 
cells (U-1690), adenylate cyclase toxin showed  
the potential to increase both cytotoxicity in both 
cell lines and to increase apoptosis, although 
cholera toxin did not induce apoptosis [35]. 
Nanoparticle-carrying bacteria 
The cargo-carrying bacteria ('microbots') is a 
novel strategy to deliver specific therapeutic 
cargo for monitoring or altering gene expression 
and protein production, using an attenuated form 
of the intracellular bacteria Listeria 
monocytogenes. Three steps are necessary to 
make nanoparticles and bacteria hybrids. First, the 
bacteria are treated making use of a biotin-
carrying antibody and thus will attach to the 
bacterial surface protein called muraminidase. 
Then, the treated bacteria are mixed by 
nanoparticles coated with streptavidin, a protein 
that binds strongly to biotin. Finally, the 
nanoparticle-loaded bacteria are mixed with 
plasmid DNA carrying biotin, which binds to the 
free strepdavidin sites on the surface of the 
nanoparticles and without any genetic 
manipulation, the microbots successfully enters 
tumor cells and releases nanoparticles, resulting in 
subsequent transcription and translation of the 
target proteins [45]. 
Nonliving bacteria 
The Bacterial Ghost (BG) platform technology is 
a creative system for vaccine, drug or DNA 
delivery vectors. BGs are non-living, non-
denatured empty cell envelops derived from 
gram-negative bacteria by controlled expression 
of the cloned lysis gene E. The role of gene E in 
the lysis of Escherichia coli was discovered in 
1966 after infection with bacteriophage X174 
[46]; following the development of genetic 
engineering technology, this hypothesis was 
confirmed [47]. E was the first lethal gene for 
bacteria which could be silenced on plasmids. 
Gene E codes for a 91-aa polypeptide and has no 
inherent enzymatic function and is able to 
produce a membrane protein with the ability to 
oligomerize into a transmembrane tunnel structure 
[48-50]. Based on the analysis of primary 
structure of protein E, it was revealed that a 
hydrophobic region at its N-terminal end is 
responsible to co-translational integration into the 
cytoplasmic membrane of E. coli [51, 52]. The 
analysis of the hydropathicity regions of protein E 
showed an E-specific lysis tunnel spanning the 
inner (IM) and outer membrane (OM), which is 
located at membrane adhesion sites within the 
host cell [53]. E-mediated lysis makes all 
cytoplasmic content release in to the environment 
while periplasmic components remain associated 
with the empty cell envelope [52]. The lysis 
tunnel diameter varies between 40 to 200 nm, 
does not indicate any regular structure, and the 
origin structure of the peptidoglycan remains 
intact [54]. A three-phase model for the process of 
E-mediated tunnel formation was described by 
Schön et al: (1) Integration of protein E into the 
IM with the C-terminal region, (2) 
Conformational change of protein E translocating 
the C-terminal domain to the Periplasmic Space 
accompanied by oligomerization, and (3) Fusion 
of IM and OM at membrane adhesion sites 
induced by exposition of the C-terminus of 
protein E to the cell surface [55]. The E-lysis 
processing could be illustrated in other gram-
negative bacteria such as Salmonella 
typhimurium, Klebsiella pneumoniae, Heliobacter 
pylori, Bordetella bronchiseptica, Vibrio 
cholerae,Haemophilus influenzae, Actinobacillus 
pleuropneumoniae, Mannheimia haemolytica, 
Pasteurella multocida, Pseudomonas putida, 
Pseudomonas aeruginosa, Pectobacterium 
cypripedii, and Ralstonia eutropha [56, 57]. 
Furthermore, previous investigations have 
indicated that DNA loaded BGs are efficiently 
engulfed, ingested, and internalized by both APCs 
and tumor cells [58]. The BG system is safe due 
to nonliving bacteria, which retains all of the 
surface morphological, structural, and antigenic 
components of their living counterparts [59]. 
Hence, it is considered as an alternative method in 
vaccine development with a new efficient gene 
delivery platform. The inner space of BGs can be 
loaded with single components, or combinations 
of peptides, drugs, or DNA [60]. BGs are able to 
deliver the heterologous genes to monocyte-
derived dendritic cells, macrophages, and 
melanoma. Cross-presentation of antigens (Ags) 
 




delivered to DCs by BGs can activate both CD4+ 
and CD8+ T cells and stimulate the immune 
system to enhance the immune response. Bacterial 
LPS augments maturation of DCs, affects 
endosomal acidification of DCs, and modifies 
cross-presentation of Ags [61, 62]. For instance, 
to prevent trachomatous conjunctivitis and 
blindness, a Chlamydia trachomatis bacterial 
ghost vaccine was produced [63].  
The obstacle of bacterial therapy 
Using bacteria as a therapeutic vehicle may cause 
some problems. First, different side effects may 
be displayed by applying live, attenuated, or 
genetically modified form of bacteria. Second, 
systemic infection of bacteria is quite problematic 
and carries higher risk of apparent toxicity. Third, 
since the bacteria cannot consume all parts of the 
malignant tissue, it is necessary to combine 
bacterial therapy with chemotherapeutic 
treatments. Fourth, the major concern is 




     The idea of using bacteria in cancer therapy 
has shown to be promising. The resistance of 
cancer cells to the drugs remains a significant 
problem. Thus, to solve this problem, bacterial 
therapy combined with cytotoxic agents has been 
proposed. Bacterial products such as toxins, 
spores, etc. are useful candidates to treat solid 
tumors. Furthermore, bacterial ghosts, microbots, 
and bactofection are the other strategies to 
destruct the malignant tissues. At last, further 
investigation and developments are being pursued 
to improve cancer treatment. 
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